Tag
A recent randomized clinical trial reveals that adjunctive intravenous ketamine significantly reduces depressive symptoms in treatment-resistant bipolar depression, with good safety and tolerability compared to midazolam.
Psilocybin-assisted psychotherapy showed promising but inconclusive antidepressant effects in treatment-resistant depression, with notable acute adverse events and safety concerns.
A randomized clinical trial finds that a 6-week ketogenic diet provides modest antidepressant effects for treatment-resistant depression compared to a healthy control diet, though long-term clinical relevance and impact on secondary outcome
In ENLIGHTEN, a biomarker-guided randomized trial, ANK3-positive patients with treatment‑resistant depression randomized to liafensine achieved larger MADRS improvements than placebo (mean difference −4.4; 95% CI −7.6 to −1.3; P = .006), wi
A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.
This review synthesizes evidence from a randomized trial and real-world studies showing esketamine’s efficacy and safety in smoking cessation among lung cancer patients with MDD, as well as in treatment-resistant depression, highlight
A UK multicentre, double-blind, placebo-controlled trial demonstrates that pramipexole augmentation at 2.5 mg reduces depressive symptoms in treatment-resistant unipolar depression at 12 weeks, with some adverse effects noted, supporting it
